Delcath Systems, Inc. Share Price & Technical Analysis
DCTH · $10.86 (-1.45%)
Healthcare / Medical Devices
$10.86
-1.45%
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development …
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
6% return in May, 37% avg return in past 3 year May month.
11% return in 2026, 64% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -2% | -10% | 7% | 11% | 6% | – | – | – | – | – | – | – | 11% |
| 25 | 28% | -7% | -11% | -5% | 34% | -16% | -21% | 4% | 0% | -9% | -1% | 6% | 2% |
| 24 | 14% | -12% | 14% | 8% | 37% | 18% | 4% | 28% | -17% | 21% | 8% | 3% | 126% |
| 23 | 3% | 39% | 18% | -3% | 40% | -27% | -24% | 7% | -11% | -20% | -12% | 56% | 65% |
| 22 | -13% | -6% | -3% | -8% | -23% | -13% | 8% | 0% | -26% | -6% | 0% | 29% | -61% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$386.64M
P/E ratio
1120
52W high
$17.35
52W low
$8.12
Volume
3,17,468
Beta
0.54
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Delcath Systems, Inc. share price today?
- Delcath Systems, Inc. (DCTH) last traded around $10.86 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does DCTH have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for DCTH. Download the app for real-time alerts.
- How can I analyze Delcath Systems, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.